Abstract Number: 1514 • ACR Convergence 2024
Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may result from a chronic pro-inflammatory state in which immunosenescent and exhausted T-lymphocytes could be involved.…Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…Abstract Number: 0389 • ACR Convergence 2024
Histopathological Features of Liver Tissue Biopsies in SJIA Patients with and Without Clinical Macrophage Activation Syndrome
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) can present with or without Macrophage Activation Syndrome (MAS), a severe, potentially life-threatening complication. Liver tissue injury is commonly…Abstract Number: 1020 • ACR Convergence 2024
Health Inequalities Exist Between the United States and Europe for Patients with Axial Spondyloarthritis
Background/Purpose: Structural differences exist between the healthcare systems in the United States (US) and Europe. In real-world clinical settings, we investigated whether these differences create…Abstract Number: 1278 • ACR Convergence 2024
The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Background/Purpose: Fatigue is a prevalent and distressing symptom in childhood-onset systemic lupus erythematosus (cSLE), affecting up to 74% of patients with potential for adverse effects…Abstract Number: 1542 • ACR Convergence 2024
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…Abstract Number: 1487 • ACR Convergence 2024
Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
Background/Purpose: To compare the pregnancy outcomes of patients with systemic lupus erythematosus (SLE) complicated with thrombocytopenia and those without, and to analyze the related risk…Abstract Number: 1523 • ACR Convergence 2024
Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
Background/Purpose: Introduction: In the past decade, the incidence of Lupus Nephritis (LN) flares linked to mortality has generally decreased, though an upward trend has emerged…Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…Abstract Number: 1502 • ACR Convergence 2024
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
Background/Purpose: Frailty, measured with the SLICC-FI, has been reported as a predictor of damage in several cohorts. The aim of this study is to evaluate…Abstract Number: 1406 • ACR Convergence 2024
Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…Abstract Number: 1503 • ACR Convergence 2024
Social Connections Among Middle-Aged and Older Adults with Systemic Lupus Erythematosus: A Single Center Cross-Sectional Study
Background/Purpose: Loneliness and social isolation have been associated with multiple adverse health outcomes in the general population of older adults. The goal of this study…Abstract Number: 0433 • ACR Convergence 2024
Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study
Background/Purpose: As reproductive health is gathering attention in rheumatology and all medical fields, the male perspective on the matter is often overlooked as not directly…
- « Previous Page
- 1
- …
- 287
- 288
- 289
- 290
- 291
- …
- 2607
- Next Page »
